allogeneic EBV-transformed B-lymphoblastoid cell line lysate-pulsed autologous dendritic cell vaccine KSD-101

{
  "id": "MLC-T-ONC-009881",
  "term": "allogeneic EBV-transformed B-lymphoblastoid cell line lysate-pulsed autologous dendritic cell vaccine KSD-101",
  "field": "Oncology and biomedicine",
  "definition": "A cell-based cancer vaccine composed of autologous monocyte-derived dendritic cells (DCs) pulsed with allogeneic Epstein-Barr virus (EBV)-transformed B-lymphoblastoid cell line (BLCL) lysate, with potential immunostimulatory and antineoplastic activities. Upon leukapheresis, DCs are loaded with allogeneic EBV-transformed BLCL lysate. Upon re-administration of the allogeneic EBV-transformed BLCL lysate-pulsed autologous DC vaccine KSD-101, the immune system is exposed to EBV-specific antigens, which stimulates the induction of a specific cytotoxic T-lymphocyte (CTL) response against EBV-positive tumor cells or EBV-infected cells. This results in cell lysis and inhibition of cancer cell proliferation. EBV, a ubiquitous human herpes virus, is associated with various malignancies.",
  "synonyms": [
    "allogeneic EBV-transformed BLCL lysate-pulsed autologous DC vaccine KSD-101"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/allogeneic-ebv-transformed-b-lymphoblastoid-cell-line-lysate-pulsed-autologous/"
}